Patents Examined by Daniel R Carcanague
  • Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same
    Patent number: 11820769
    Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: November 21, 2023
    Assignee: YUHAN CORPORATION
    Inventors: Tae Dong Han, Hee Jae Tak, Eun Kyung Kim, Dong Hoon Kim, Su Bin Choi, Sol Park, Hyun Ho Choi, Tae Wang Kim, Mi Kyeong Ju, Na Ry Ha
  • Organic compound and electrochromic element
    Patent number: 11815778
    Abstract: An organic compound that absorbs light of a wavelength range from 450 nm to 580 nm in a reduction state and is colored and that is superior in high-temperature drive durability and that is expressed by the following formula [1]. Z1 and Z2 each represent a substituent. R11 to R18 each represent a hydrogen atom or a substituent. R12 and R13 are optionally bound to each other to form a ring. R21 and R22 each represent a hydrogen atom or a substituent. X? represents an anion, and n is an integer greater than or equal to 1. When n is 2 or greater, two or more X?s are the same or different from each other.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: November 14, 2023
    Assignee: Canon Kabushiki Kaisha
    Inventors: Kenji Yamada, Satoshi Igawa, Kazuho Saeki
  • Compounds and compositions for use in treating skin disorders
    Patent number: 11807621
    Abstract: Provided herein is a compound of formula (XXXII) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer thereof or a physiologically functional derivative thereof, wherein R1, R2, R3, G, A, E, n, p, and q are defined herein. Also provided herein are compositions comprising a compound of formula (XXXII), and methods of using a compound of formula (XXXII), e.g., in the treatment or prevention of skin disorders.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: November 7, 2023
    Assignee: KAMARI PHARMA LTD.
    Inventors: Xinyuan Wu, Bertrand L. Chenard, Nili Claudia Schutz, Dov Terkieltaub
  • Combination therapy of Axl inhibitor and EGFR tyrosine kinase inhibitor
    Patent number: 11806339
    Abstract: The present invention provides a medicament comprising a compound represented by general formula (1) which has Axl inhibitory activity, and an EGFR tyrosine kinase inhibitor in combination, and a method for treating cancer using this combination. The present invention provides an excellent medicament and method for treating cancer which is highly effective for inhibiting resistance to an EGFR tyrosine kinase inhibitor in cancer treatment, and causes less adverse reactions such as weight loss.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: November 7, 2023
    Assignee: Daiichi Sankyo Company, Limited
    Inventor: Takeshi Jimbo
  • Therapeutic inhibition affinity of copper (II) complex and their diazenyl pyridinone heterocyclic ligands against SARS-CoV2
    Patent number: 11786537
    Abstract: Methods of using copper (II) complexes of Formula I to prevent and/or treat coronavirus infections, such as SARS-CoV-2 infections, are provided. In Formula I, Y is NO2 or CH3 and X is a C1 to C20 hydrocarbon which is optionally substituted. The copper (II) complexes bind to an inactivate proteins that are necessary for the virus to successfully establish an infection and reproduce.
    Type: Grant
    Filed: February 13, 2022
    Date of Patent: October 17, 2023
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Khadijah M. Al-Zaydi, Mostafa A. Hussien A. Hussein, Ahlam Ibrahim Alsulami
  • Delta-opioid receptor agonists
    Patent number: 11787787
    Abstract: The present disclosure relates to novel ?-opioid receptor agonists, and the method of making and using the novel ?-opioid receptor agonists. The novel ?-opioid receptor agonists are selective ?-opioid receptor agonists that have substantially no beta-arrestin 2 recruitment or low beta-arrestin 2 recruitment. The novel ?-opioid receptor agonists may be used for the treatment for alcohol use disorders and other co-occurring psychiatric disorders.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: October 17, 2023
    Assignee: Purdue Research Foundation
    Inventors: Richard M Van Rijn, Mark S Cushman, Markus Lill, Robert J Cassell, Amr Hamed Mahmoud Abdallah, Mohamed S. A. Elsayed
  • Tetrahydroquinoline-based bromodomain inhibitors
    Patent number: 11787768
    Abstract: In one aspect, compounds and compositions that modulate a bromodomain and methods of making and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with inhibition of a bromodomain such as, for example, cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: October 17, 2023
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: R. Kip Guy, P Jake Slavish, William Robert Shadrick, Brandon M. Young, Vincent A. Boyd, Nagakumar Bharatham, Jeanine E. Price, Anang Shelat
  • 4,5-annulated 1,2,4-triazolones
    Patent number: 11787797
    Abstract: The present invention provides triazolone compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: October 17, 2023
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE GENERAL HOSPITAL CORPORATION
    Inventors: Stefan Nikolaus Gradl, Duy Nguyen, Knut Eis, Judith Günther, Timo Stellfeld, Andreas Janzer, Sven Christian, Thomas Mueller, Sherif El Sheikh, Han Jie Zhou, Changjia Zhao, David B. Sykes, Steven James Ferrara, Kery Liu, Simon Anthony Herbert, Claudia Merz, Michael Niehues, Carl Friedrich Nising, Martina Schäfer, Katja Zimmermann, Jörg Knäblein, Kai Thede, Thomas Faupel
  • Organic electroluminescent materials and devices
    Patent number: 11793066
    Abstract: Phosphorescent complexes are designed with intramolecular H-bonding properties to prevent deprotonation of neighboring molecules.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: October 17, 2023
    Assignee: Universal Display Corporation
    Inventors: Hsiao-Fan Chen, Scott Beers, Geza Szigethy, Jason Brooks
  • Potent antiviral pyrazolopyridine compounds
    Patent number: 11787799
    Abstract: The present technology provides compounds according to Formulas (I), (II), or (III) useful in inhibiting an enterovirus, paramyxovirus, respiratory virus, flaviviridae virus, bunyaviridae virus, togaviridae virus, or rabies virus in a cell and/or treating subjects suffering from an enterovirus, paramyxovirus, respiratory virus, flaviviridae virus, bunyaviridae virus, togaviridae virus, or rabies virus.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: October 17, 2023
    Assignee: The Regents of the University of California
    Inventors: Paul Krogstad, Michael E. Jung, Jun Zuo, Yanpeng Xing
  • Process for preparation of soluble guanylate cyclase stimulators
    Patent number: 11773089
    Abstract: The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula (I), including Compound (I), in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: October 3, 2023
    Assignee: Cyclerion Therapeutics, Inc.
    Inventors: Song Xue, Vishnu Vardhan Reddy Karnati, Robert C. Livingston
  • Small molecule regulators of mitochondrial fusion and methods of use thereof
    Patent number: 11760733
    Abstract: Compositions comprising small molecule mitofusin agonists are described. The mitofusin modulating agents are useful for treating diseases or disorders associated with a mitochondria-associated disease, disorder, or condition such as diseases or disorders associated with mitofusin 1 (Mfn1) and/or mitofusin 2 (Mfn2), or mitochondrial dysfunction. Methods of treatment, pharmaceutical formulations, and screening methods for identifying compounds that regulate mitochondrial function are also described.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: September 19, 2023
    Assignee: Washington University
    Inventor: Gerald W. Dorn, II
  • Inhibitors of receptor interacting protein kinase I for the treatment of disease
    Patent number: 11753381
    Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: September 12, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Michael Hamilton, William J. Ray, Fernando Alvarez, Dana E. Pfaffinger, Naphtali Reyna, Jason Cross, Suyambu Kesava Vijayan Ramaswamy
  • Bryostatin compounds and methods of preparing the same
    Patent number: 11746105
    Abstract: Methods for preparing a variety of bryostatin compounds are provided. The subject methods provide for preparation of bryostatin 1 in multi-gram quantities in a low and unprecedented number of convergent synthetic steps from commercially available materials. The subject methods are scalable with low estimated material costs and can provide enough material to meet clinical needs. Also provided are a variety of bryostatin analog compounds, and prodrug forms thereof, which are synthetically accessible via the subject methods and pharmaceutical compositions including the same.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: September 5, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Paul Wender, Ryan Quiroz, Stephen Ho, Akira Shimizu, Steven Ryckbosch, Matthew C. Stevens, Matthew S. Jeffreys, Clayton Hardman, Jack Sloane
  • Process for the production of 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methyl-morpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine
    Patent number: 11746107
    Abstract: The present invention relates to a process for the synthesis of 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine in two hydrated crystalline forms and in one anhydrous crystalline form. The present invention further relates to methyl (Z)-4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)-N-cyanopiperidine-1-carbimidothioate which is an intermediate in this process.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: September 5, 2023
    Assignee: Molecure S.A.
    Inventors: Grzegorz Witkowski, Marta Magdycz, Magdalena Tyszkiewicz, Marcin Zakrzewski, Stanislaw Pikul
  • Phenyl propionic acid derivatives and uses thereof
    Patent number: 11731961
    Abstract: Compounds of Formula (I), racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions containing the compounds, racemates, enantiomers, diastereomers thereof are disclosed. These compounds have GPR40 agonist activity and are capable of modulating blood glucose levels and glucose-dependent insulin secretion mechanism, and, thus, exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. These compounds could be used in preventing and/or treating type 2 diabetes through adequate control of blood glucose.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: August 22, 2023
    Assignee: ILDONG PHARMACEUTICAL CO., LTD.
    Inventors: Jae-Hoon Kang, Hong-Sub Lee, Kyung-Mi An, Chang-Hee Hong, Hyun-Jung Kwak, Shuo-Lin Cui, Hyo-Jung Song
  • Compositions and methods for Williams Syndrome (WS) therapy
    Patent number: 11730769
    Abstract: The present disclosure relates to compositions and methods for treating Williams syndrome (WS), herein identified as a neurodevelopmental oligodendrocyte hypomyelination-associated disease, and to compositions and methods for treatment of other neurodevelopmental myelination abnormality diseases or disorders.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: August 22, 2023
    Assignees: Children's Medical Center Corporation, Massachusetts Institute of Technology
    Inventors: Guoping Feng, Boaz Barak, Zhigang He
  • ALK5 inhibitors
    Patent number: 11730720
    Abstract: The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: August 22, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Svitlana Kulyk, Christina Owens, Steven D. E. Sullivan, Jennifer Kozak, Adam D. Hughes
  • Synthesis of intermediates for the preparation of alpha-tocopherol
    Patent number: 11724996
    Abstract: The present invention relates to a novel synthetic pathway for alpha-tocopherol. The invention discloses different reactions yielding some new intermediates in a very high yield and stereoselectivity.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: August 15, 2023
    Assignee: DSM IP ASSETS B.V.
    Inventors: Ulla Letinois, Thomas Netscher, August Ruettimann
  • Therapeutic dendrimers
    Patent number: 11717574
    Abstract: Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: August 8, 2023
    Assignee: ASTRAZENECA AB
    Inventors: Marianne Bernice Ashford, Iain Grant, Edward John Hennessy, William Mccoull, Michael Giannis, Brian Kelly, David Owen, John Paul Secrist